Q2 2020

Filed Aug 14, 2020 · 10-Q · 45 days after period end · 0001654954-20-009164

Q2 2020 · 10-Q

Revenue—

Net Income

-$2.89M

N/M vs Q2 2019

EPS Diluted

-$0.20

N/M vs Q2 2019

Operating Income-$2,891,279N/M

Operating Cash Flowderived-$3,451,665N/M

Same quarter

Metric	Q2 2020	Q2 2019	Q2 2018	Q2 2017
Revenue	—	$0.00	$0.00	$57.77K
Net Income	-$2.89M	-$2.33M	-$1.85M	-$1.43M
EPS Diluted	-$0.20	-$0.31	-$0.47	-$0.59

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR